STOCK TITAN

[Form 4] NetFlix Inc Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing overview: On 06/30/2025, Inhibikase Therapeutics, Inc. (IKT) granted Director Arvind Kush a stock option for 108,176 shares of common stock at an exercise price of $1.95 per share. The option is classified as a derivative security and is held directly by the reporting person.

Vesting & expiration: The option vests on the earlier of (i) June 30, 2026 or (ii) the day before the company’s next annual shareholder meeting, provided the director remains in service through that date. It expires on 06/30/2032.

Post-grant ownership: Following the transaction, Kush beneficially owns 108,176 derivative securities (options) with no change in non-derivative share holdings disclosed. No shares were sold or disposed of in this filing.

Key takeaway: The filing reflects routine director compensation, increasing insider exposure to future share-price appreciation without immediate cash outflow.

Panoramica della presentazione del Modulo 4: Il 30/06/2025, Inhibikase Therapeutics, Inc. (IKT) ha concesso al Direttore Arvind Kush un opzione su azioni per 108.176 azioni ordinarie a un prezzo di esercizio di 1,95 $ per azione. L'opzione è classificata come titolo derivato ed è detenuta direttamente dalla persona che effettua la segnalazione.

Vesting e scadenza: L'opzione matura al primo verificarsi tra (i) il 30 giugno 2026 o (ii) il giorno precedente la prossima assemblea annuale degli azionisti della società, a condizione che il direttore rimanga in carica fino a quella data. Scade il 30/06/2032.

Proprietà dopo la concessione: A seguito della transazione, Kush detiene beneficiariamente 108.176 titoli derivati (opzioni) senza variazioni nelle azioni non derivanti dichiarate. Nessuna azione è stata venduta o ceduta in questa comunicazione.

Conclusione principale: La presentazione riflette una normale compensazione del direttore, aumentando l'esposizione interna all'apprezzamento futuro del prezzo delle azioni senza un esborso di denaro immediato.

Resumen de la presentación del Formulario 4: El 30/06/2025, Inhibikase Therapeutics, Inc. (IKT) otorgó al Director Arvind Kush una opción sobre acciones por 108,176 acciones ordinarias con un precio de ejercicio de $1.95 por acción. La opción se clasifica como un valor derivado y está en posesión directa de la persona que reporta.

Consolidación y vencimiento: La opción se consolida en la fecha que ocurra primero entre (i) el 30 de junio de 2026 o (ii) el día antes de la próxima junta anual de accionistas de la compañía, siempre que el director continúe en servicio hasta esa fecha. Expira el 30/06/2032.

Propiedad posterior a la concesión: Tras la transacción, Kush posee beneficiariamente 108,176 valores derivados (opciones) sin cambios en las acciones no derivadas declaradas. No se vendieron ni dispusieron acciones en esta presentación.

Conclusión clave: La presentación refleja una compensación rutinaria para el director, aumentando la exposición interna a la apreciación futura del precio de las acciones sin un desembolso de efectivo inmediato.

양식 4 제출 개요: 2025년 6월 30일, Inhibikase Therapeutics, Inc.(IKT)는 이사 Arvind Kush에게 108,176주의 보통주 스톡옵션을 주당 1.95달러의 행사가격으로 부여했습니다. 이 옵션은 파생증권으로 분류되며 보고자가 직접 보유하고 있습니다.

베스팅 및 만료: 옵션은 (i) 2026년 6월 30일 또는 (ii) 회사의 다음 연례 주주총회 전날 중 빠른 날짜에 베스팅되며, 이사는 해당 날짜까지 재직 중이어야 합니다. 만료일은 2032년 6월 30일입니다.

부여 후 소유권: 거래 후 Kush는 108,176개의 파생증권(옵션)을 실질적으로 소유하고 있으며, 비파생주식 보유에는 변동이 없습니다. 이번 제출에서 주식 매도나 처분은 없었습니다.

주요 내용: 이번 제출은 일상적인 이사 보상을 반영하며, 즉각적인 현금 지출 없이 내부자의 향후 주가 상승 노출을 증가시킵니다.

Présentation générale du formulaire 4 : Le 30/06/2025, Inhibikase Therapeutics, Inc. (IKT) a accordé au directeur Arvind Kush une option d'achat portant sur 108 176 actions ordinaires au prix d'exercice de 1,95 $ par action. L'option est classée comme un titre dérivé et est détenue directement par la personne déclarante.

Acquisition des droits et expiration : L'option devient acquise à la première des deux dates suivantes : (i) le 30 juin 2026 ou (ii) la veille de la prochaine assemblée annuelle des actionnaires, sous réserve que le directeur soit toujours en fonction à cette date. Elle expire le 30/06/2032.

Propriété après attribution : Suite à la transaction, Kush détient bénéficiairement 108 176 titres dérivés (options) sans modification des actions non dérivées déclarées. Aucune action n'a été vendue ou cédée dans cette déclaration.

Point clé : Cette déclaration reflète une rémunération habituelle du directeur, augmentant l'exposition interne à la valorisation future des actions sans sortie de trésorerie immédiate.

Übersicht der Form 4 Einreichung: Am 30.06.2025 gewährte Inhibikase Therapeutics, Inc. (IKT) dem Direktor Arvind Kush eine Aktienoption über 108.176 Aktien des Stammkapitals zu einem Ausübungspreis von 1,95 $ pro Aktie. Die Option wird als Derivatwertpapier klassifiziert und vom meldepflichtigen Personen direkt gehalten.

Vesting & Ablauf: Die Option wird zum früheren Zeitpunkt von (i) 30. Juni 2026 oder (ii) dem Tag vor der nächsten jährlichen Hauptversammlung der Gesellschaft fällig, vorausgesetzt der Direktor bleibt bis zu diesem Datum im Amt. Sie läuft am 30.06.2032 ab.

Eigentum nach Gewährung: Nach der Transaktion besitzt Kush wirtschaftlich 108.176 derivative Wertpapiere (Optionen) ohne Änderungen bei den nicht-derivativen Aktienbeständen. Es wurden keine Aktien verkauft oder veräußert in dieser Meldung.

Wichtigster Punkt: Die Meldung spiegelt eine routinemäßige Vergütung des Direktors wider und erhöht die Insider-Exponierung gegenüber zukünftigen Kurssteigerungen ohne sofortigen Geldabfluss.

Positive
  • Director received 108,176 stock options, increasing long-term equity exposure and aligning board incentives with shareholder interests.
  • No shares were sold or disposed of, indicating commitment rather than profit-taking.
Negative
  • None.

Insights

TL;DR Routine option grant; aligns director incentives, no immediate share sale, neutral near-term market impact.

The grant of 108,176 options at $1.95 is standard board compensation and does not involve cash transactions or stock disposals. The one-year vesting schedule ensures continued board engagement. Because no open-market buying or selling occurred, the filing is largely informational with minimal trading signal. The size of the grant is modest for a micro-cap biotech and does not materially change insider ownership percentages disclosed elsewhere. Overall, the filing is neutral for valuation but slightly positive for governance alignment.

Panoramica della presentazione del Modulo 4: Il 30/06/2025, Inhibikase Therapeutics, Inc. (IKT) ha concesso al Direttore Arvind Kush un opzione su azioni per 108.176 azioni ordinarie a un prezzo di esercizio di 1,95 $ per azione. L'opzione è classificata come titolo derivato ed è detenuta direttamente dalla persona che effettua la segnalazione.

Vesting e scadenza: L'opzione matura al primo verificarsi tra (i) il 30 giugno 2026 o (ii) il giorno precedente la prossima assemblea annuale degli azionisti della società, a condizione che il direttore rimanga in carica fino a quella data. Scade il 30/06/2032.

Proprietà dopo la concessione: A seguito della transazione, Kush detiene beneficiariamente 108.176 titoli derivati (opzioni) senza variazioni nelle azioni non derivanti dichiarate. Nessuna azione è stata venduta o ceduta in questa comunicazione.

Conclusione principale: La presentazione riflette una normale compensazione del direttore, aumentando l'esposizione interna all'apprezzamento futuro del prezzo delle azioni senza un esborso di denaro immediato.

Resumen de la presentación del Formulario 4: El 30/06/2025, Inhibikase Therapeutics, Inc. (IKT) otorgó al Director Arvind Kush una opción sobre acciones por 108,176 acciones ordinarias con un precio de ejercicio de $1.95 por acción. La opción se clasifica como un valor derivado y está en posesión directa de la persona que reporta.

Consolidación y vencimiento: La opción se consolida en la fecha que ocurra primero entre (i) el 30 de junio de 2026 o (ii) el día antes de la próxima junta anual de accionistas de la compañía, siempre que el director continúe en servicio hasta esa fecha. Expira el 30/06/2032.

Propiedad posterior a la concesión: Tras la transacción, Kush posee beneficiariamente 108,176 valores derivados (opciones) sin cambios en las acciones no derivadas declaradas. No se vendieron ni dispusieron acciones en esta presentación.

Conclusión clave: La presentación refleja una compensación rutinaria para el director, aumentando la exposición interna a la apreciación futura del precio de las acciones sin un desembolso de efectivo inmediato.

양식 4 제출 개요: 2025년 6월 30일, Inhibikase Therapeutics, Inc.(IKT)는 이사 Arvind Kush에게 108,176주의 보통주 스톡옵션을 주당 1.95달러의 행사가격으로 부여했습니다. 이 옵션은 파생증권으로 분류되며 보고자가 직접 보유하고 있습니다.

베스팅 및 만료: 옵션은 (i) 2026년 6월 30일 또는 (ii) 회사의 다음 연례 주주총회 전날 중 빠른 날짜에 베스팅되며, 이사는 해당 날짜까지 재직 중이어야 합니다. 만료일은 2032년 6월 30일입니다.

부여 후 소유권: 거래 후 Kush는 108,176개의 파생증권(옵션)을 실질적으로 소유하고 있으며, 비파생주식 보유에는 변동이 없습니다. 이번 제출에서 주식 매도나 처분은 없었습니다.

주요 내용: 이번 제출은 일상적인 이사 보상을 반영하며, 즉각적인 현금 지출 없이 내부자의 향후 주가 상승 노출을 증가시킵니다.

Présentation générale du formulaire 4 : Le 30/06/2025, Inhibikase Therapeutics, Inc. (IKT) a accordé au directeur Arvind Kush une option d'achat portant sur 108 176 actions ordinaires au prix d'exercice de 1,95 $ par action. L'option est classée comme un titre dérivé et est détenue directement par la personne déclarante.

Acquisition des droits et expiration : L'option devient acquise à la première des deux dates suivantes : (i) le 30 juin 2026 ou (ii) la veille de la prochaine assemblée annuelle des actionnaires, sous réserve que le directeur soit toujours en fonction à cette date. Elle expire le 30/06/2032.

Propriété après attribution : Suite à la transaction, Kush détient bénéficiairement 108 176 titres dérivés (options) sans modification des actions non dérivées déclarées. Aucune action n'a été vendue ou cédée dans cette déclaration.

Point clé : Cette déclaration reflète une rémunération habituelle du directeur, augmentant l'exposition interne à la valorisation future des actions sans sortie de trésorerie immédiate.

Übersicht der Form 4 Einreichung: Am 30.06.2025 gewährte Inhibikase Therapeutics, Inc. (IKT) dem Direktor Arvind Kush eine Aktienoption über 108.176 Aktien des Stammkapitals zu einem Ausübungspreis von 1,95 $ pro Aktie. Die Option wird als Derivatwertpapier klassifiziert und vom meldepflichtigen Personen direkt gehalten.

Vesting & Ablauf: Die Option wird zum früheren Zeitpunkt von (i) 30. Juni 2026 oder (ii) dem Tag vor der nächsten jährlichen Hauptversammlung der Gesellschaft fällig, vorausgesetzt der Direktor bleibt bis zu diesem Datum im Amt. Sie läuft am 30.06.2032 ab.

Eigentum nach Gewährung: Nach der Transaktion besitzt Kush wirtschaftlich 108.176 derivative Wertpapiere (Optionen) ohne Änderungen bei den nicht-derivativen Aktienbeständen. Es wurden keine Aktien verkauft oder veräußert in dieser Meldung.

Wichtigster Punkt: Die Meldung spiegelt eine routinemäßige Vergütung des Direktors wider und erhöht die Insider-Exponierung gegenüber zukünftigen Kurssteigerungen ohne sofortigen Geldabfluss.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Dopfner Mathias

(Last) (First) (Middle)
121 ALBRIGHT WAY

(Street)
LOS GATOS CA 95032

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NETFLIX INC [ NFLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right to buy) $1,293.6 07/01/2025 A 49 07/01/2025 07/01/2035 Common Stock 49 $0 49 D
Explanation of Responses:
Remarks:
By: Veronique Bourdeau, Authorized Signatory For: Mathias Dopfner 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for IKT report on 06/30/2025?

Director Arvind Kush received an option to purchase 108,176 shares at $1.95.

When do the newly granted IKT options vest?

They vest on the earlier of June 30, 2026 or the day before the next annual shareholder meeting.

Did the insider sell any Inhibikase shares?

No. The Form 4 shows only an option grant; there were no disposals.

What is the expiration date of the IKT options granted to Arvind Kush?

The options expire on June 30, 2032.

How many derivative securities does Arvind Kush own after the transaction?

He beneficially owns 108,176 derivative securities (stock options).
Netflix Inc

NASDAQ:NFLX

NFLX Rankings

NFLX Latest News

NFLX Latest SEC Filings

NFLX Stock Data

532.22B
423.21M
0.75%
86.4%
1.72%
Entertainment
Services-video Tape Rental
Link
United States
LOS GATOS